Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced CancersPatricia LoRusso, Alejandro D. Ricart, Smitha Krishnamurthi et al.|Clinical Cancer Research|2010Cited by 250
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregiversLaurel Northouse, Trace Kershaw, Darlene Mood et al.|Psycho-Oncology|2012Cited by 238
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J. Lakhani, Wells A. Messersmith, Laura Q.M. Chow et al.|Seoul National University Open Repository (Seoul National University)|2021Cited by 95
Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid TumorsToshio Shimizu, Anthony W. Tolcher, Jing Wang et al.|Clinical Cancer Research|2014Cited by 82
Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trialToru Mukohara, Patricia LoRusso|Nature Medicine|2024Cited by 50